文献速递免疫规划传染病防控与疫情报告

中国甲肝灭活与减毒活疫苗长期血清阳性率、安全性及影响:横断面研究

Long-term seropositivity, safety, and impact of inactivated and live, attenuated hepatitis a vaccines in China - A cross-sectional study.
PubMed 文献 · Vaccine · 2020-11-16

该研究利用1992年和2014年全国血清学调查及国家监测系统数据,比较甲肝灭活疫苗(I-HepA)与减毒活疫苗(L-HepA)的长期血清阳性率、安全性和对甲肝发病率的影响。接种后1年I-HepA血清阳性率(97.8%)显著高于L-HepA(90.7%),10年后分别降至75.4%和73.5%且无显著差异;两种疫苗严重AEFI年发生率均<0.5/10万。结论支持继续在扩大免疫规划中使用两种疫苗。

要点

  • 接种后1年I-HepA血清阳性率97.8%,显著高于L-HepA的90.7%。
  • 10年后血清阳性率I-HepA为75.4%、L-HepA为73.5%,无显著差异。
  • 两种疫苗严重AEFI年发生率均<0.5/10万。

核心结论

  • 良好的免疫原性、安全性和对发病率的影响证据支持继续在EPI系统中使用I-HepA和L-HepA。
  • 研究结果可能对考虑将甲肝疫苗纳入常规免疫规划的国家有用。

研究设计与样本

  • 横断面研究,利用两次全国血清学调查(1992年和2014年)、2014年血清学调查的接种状态及国家监测系统的疫苗安全性和疾病发病率数据。
  • 将31个省份分为三组:主要使用I-HepA且高覆盖(n=4)、主要使用L-HepA且高覆盖(n=4)、主要使用L-HepA且较低覆盖(n=23)。
  • 比较疫苗受种者的长期HAV血清阳性率,并描述两种疫苗的安全性特征。

主要发现

  • 接种后1年,I-HepA血清阳性率显著高于L-HepA(97.8% vs 90.7%)。
  • 10年后,L-HepA血清阳性率降至73.5%,I-HepA降至75.4%,两者无显著差异。
  • 两种疫苗严重AEFI年发生率均<0.5/10万。
  • 在任一甲肝疫苗许可前,后来主要使用I-HepA的省份甲肝发病率和HAV血清阳性率低于后来使用L-HepA的省份,到2014年这些差异显著缩小。
  • 无论疫苗选择如何,三组省份中在全国疫苗引入前10年内出生者(2014年10-24岁)的HAV免疫力均较低。

临床怎么用

  • 两种甲肝疫苗均可继续用于常规免疫规划,选择时可参考当地流行病学与实施条件。
  • 应关注全国疫苗引入前10年内出生人群的较低HAV免疫力,适时评估补充免疫需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2008, China introduced live, attenuated hepatitis A vaccine (L-HepA, licensed in 1992) and inactivated hepatitis A vaccine (I-HepA, licensed in 2002) nationwide, and is currently the only country using L-HepA in routine immunization. We assessed seropositivity and its duration following vaccination, safety, and association with hepatitis A incidence and population seroprevalence for I-HepA and L-HepA. METHODS: We obtained seroprevalence data from two nationwide serosurveys (in 1992 and 2014), vaccination status from the 2014 serosurvey, and vaccine safety and disease incidence data from the national surveillance system. We compared long-term HAV seropositivity among vaccine recipients and described safety profiles of both vaccines. We categorized the 31 provinces into those predominately using I-HepA and achieving high coverage (n = 4), those predominately using L-HepA achieving high coverage (n = 4), and those predominately using L-HepA achieving lower coverage (n = 23). We compared population HAV seropositivity, coverage, and disease incidence among the three groups. RESULTS: One year after vaccination, seropositivity from I-HepA was significantly higher than from L-HepA (97.8% vs 90.7%), and seropositivity declined to 73.5% for L-HepA and 75.4% for I-HepA after 10 years - not significantly different by vaccine. The annual incidence of serious AEFI was <0.5/100 000 for both vaccines. Prior to licensure of either HepA vaccine, provinces that would go on to predominantly use I-HepA had lower incidences of hepatitis A and lower seropositivity levels to HAV than provinces that would go on to use L-HepA. By 2014, these differences were significantly diminished. Regardless of vaccine selection, all three province groups had lower immunity to HAV among individuals born during the 10 years prior to nationwide vaccine introduction - individuals who were 10 to 24 years old in 2014. CONCLUSION: Evidence of good immunogenicity, safety, and impact on incidence supports continued use of both I-HepA and L-HepA in the EPI system. These results may be useful for countries considering integrating HepA vaccines into their routine programs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Xiaojin S, Rodewald LE, Guomin Z, et al. Long-term seropositivity, safety, and impact of inactivated and live, attenuated hepatitis a vaccines in China - A cross-sectional study. Vaccine. 2020. PMID: 33213930. doi:10.1016/j.vaccine.2020.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。